{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:41:27Z","timestamp":1771580487952,"version":"3.50.1"},"reference-count":102,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IPO Porto","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"IPO Porto","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"IPO Porto","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"name":"European Social Funds (FSE)","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"European Social Funds (FSE)","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"European Social Funds (FSE)","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"name":"national funds of MCTES","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"national funds of MCTES","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"national funds of MCTES","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"name":"FCT\/MCTES","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"FCT\/MCTES","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"FCT\/MCTES","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer (OC) and venous thromboembolism (VTE) have a close relationship, in which tumour cells surpass the haemostatic system to drive cancer progression. Long non-coding RNAs (lncRNAs) have been implicated in VTE pathogenesis, yet their roles in cancer-associated thrombosis (CAT) and their prognostic value are unexplored. Understanding how these lncRNAs influence venous thrombogenesis and ovarian tumorigenesis may lead to the identification of valuable biomarkers for VTE and OC management. Thus, this study evaluated the impact of five lncRNAs, namely MALAT1, TUG1, NEAT1, XIST and MEG8, on a cohort of 40 OC patients. Patients who developed VTE after OC diagnosis had worse overall survival compared to their counterparts (log-rank test, p = 0.028). Elevated pre-chemotherapy MEG8 levels in peripheral blood cells (PBCs) predicted VTE after OC diagnosis (Mann\u2013Whitney U test, p = 0.037; \u03a72 test, p = 0.033). In opposition, its low levels were linked to a higher risk of OC progression (adjusted hazard ratio (aHR) = 3.00; p = 0.039). Furthermore, low pre-chemotherapy NEAT1 levels in PBCs were associated with a higher risk of death (aHR = 6.25; p = 0.008). As for the remaining lncRNAs, no significant association with VTE incidence, OC progression or related mortality was observed. Future investigation with external validation in larger cohorts is needed to dissect the implications of the evaluated lncRNAs in OC patients.<\/jats:p>","DOI":"10.3390\/ijms25010140","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T08:16:02Z","timestamp":1703146562000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long Non-Coding RNAs: Bridging Cancer-Associated Thrombosis and Clinical Outcome of Ovarian Cancer Patients"],"prefix":"10.3390","volume":"25","author":[{"given":"In\u00eas Soares","family":"Marques","sequence":"first","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Faculty of Sciences of the University of Porto (FCUP), 4169-007 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-7757","authenticated-orcid":false,"given":"Val\u00e9ria","family":"Tavares","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"given":"Joana","family":"Savva-Bordalo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Mariana","family":"Rei","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-4180","authenticated-orcid":false,"given":"Joana","family":"Liz-Pimenta","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Department of Medical Oncology, Centro Hospitalar de Tr\u00e1s-os-Montes e Alto Douro (CHTMAD), 5000-508 Vila Real, Portugal"}]},{"given":"In\u00eas Guerra","family":"de Melo","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-7161","authenticated-orcid":false,"given":"Joana","family":"Assis","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, 4050-313 Porto, Portugal"},{"name":"Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"},{"name":"Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian Cancer: An Integrated Review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2016.12.002","article-title":"Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progresion","volume":"150","author":"Swier","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/cncr.23425","article-title":"Improved survival time: What can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tavares, V., Pinto, R., Assis, J., Pereira, D., and Medeiros, R. (2020). Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. Biochim. Biophys. Acta (BBA)-Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2019.188331"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1373\/clinchem.2012.185363","article-title":"Targeting the tumor microenvironment for cancer therapy","volume":"59","author":"Sounni","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S11285","DOI":"10.4137\/CGM.S11285","article-title":"Regulation of tumor growth and metastasis: The role of tumor microenvironment","volume":"7","author":"Goubran","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2017.08.003","article-title":"Mechanisms and risk factors of thrombosis in cancer","volume":"118","author":"Falanga","year":"2017","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103989","DOI":"10.1016\/j.critrevonc.2023.103989","article-title":"Thrombosis and cachexia in cancer: Two partners in crime?","volume":"186","author":"Tavares","year":"2023","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Abdol Razak, N.B., Jones, G., Bhandari, M., Berndt, M.C., and Metharom, P. (2018). Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers, 10.","DOI":"10.3390\/cancers10100380"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Stoiber, D., and Assinger, A. (2020). Platelet-Leukocyte Interplay in Cancer Develop-ment and Progression. Cells, 9.","DOI":"10.3390\/cells9040855"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1144229","DOI":"10.3389\/fimmu.2023.1144229","article-title":"Endothelial dysfunction and immunothrombosis in sepsis","volume":"14","author":"Maneta","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"863846","DOI":"10.3389\/fcvm.2022.863846","article-title":"Implication of platelets in immuno-thrombosis and thrombo-inflammation","volume":"9","author":"Zaid","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58S","DOI":"10.1378\/chest.124.3_suppl.58S","article-title":"Tissue factor, thrombin, and cancer","volume":"124","author":"Rickles","year":"2003","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","article-title":"Procoagulant mechanisms in tumour cells","volume":"22","author":"Falanga","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global Burden of Thrombosis","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjc.6601964","article-title":"Excess risk of cancer in patients with primary venous thromboembolism: A national, population-based cohort study","volume":"91","author":"Murchison","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1160\/TH16-10-0823","article-title":"Venous thromboembolism: Past, present and future","volume":"117","author":"Schulman","year":"2017","journal-title":"Thromb. Haemost"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Marques, I.S., Tavares, V., Neto, B.V., Mota, I.N.R., Pereira, D., and Medeiros, R. (2023). Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512103"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.06.004","article-title":"Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival","volume":"170","author":"Saadeh","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2019.07.027","article-title":"Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study","volume":"181","author":"Kahr","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/ijgc-2019-000980","article-title":"Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer","volume":"30","author":"Salinaro","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2374716","DOI":"10.1155\/2020\/2374716","article-title":"Meta-Analysis of VTE Risk: Ovarian Cancer Patients by Stage, Histology, Cytoreduction, and Ascites at Diagnosis","volume":"2020","author":"Weeks","year":"2020","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2021.07.030","article-title":"Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy","volume":"163","author":"Basaran","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/aogs.14246","article-title":"Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study","volume":"100","author":"Oxley","year":"2021","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Glassman, D., Bateman, N.W., Lee, S., Zhao, L., Yao, J., Tan, Y., Ivan, C., Rangel, K.M., Zhang, J., and Conrads, K.A. (2022). Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers, 14.","DOI":"10.3390\/cancers14061496"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.ygyno.2023.08.003","article-title":"Universal thromboprophylaxis in ovarian cancer patients before and after surgery?","volume":"176","author":"Moufarrij","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/IGC.0000000000000415","article-title":"High pretreatment plasma D-dimer levels are associated with poor prognosis in patients with ovarian cancer independently of venous thromboembolism and tumor extension","volume":"25","author":"Sakurai","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/IGC.0b013e31827b8796","article-title":"Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer","volume":"23","author":"Tas","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ygyno.2010.12.139","article-title":"True blood: Platelets as a biomarker of ovarian cancer recurrence","volume":"120","author":"Lutgendorf","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.bjc.6603552","article-title":"Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer","volume":"96","author":"Uno","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2013.09.016","article-title":"Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer-relationship with venous thrombosis risk","volume":"132","author":"Saadeh","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.113.11.1","article-title":"Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer","volume":"11","author":"Wang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41397-020-00201-9","article-title":"Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients","volume":"21","author":"Tavares","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cuff, J., Salari, K., Clarke, N., Esheba, G.E., Forster, A.D., Huang, S., West, R.B., Higgins, J.P., Longacre, T.A., and Pollack, J.R. (2013). Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074562"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2013.09.005","article-title":"Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival","volume":"131","author":"Diaz","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2015.11.030","article-title":"Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases","volume":"137","author":"Heath","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1248\/yakushi.20-00228","article-title":"Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review","volume":"141","author":"Nishimura","year":"2021","journal-title":"Yakugaku Zasshi J. Pharm. Soc. Jpn."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2017.10.012","article-title":"Long non-coding RNAs in the atherosclerotic plaque","volume":"266","author":"Arslan","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_42","first-page":"3138","article-title":"Long non-coding RNA MALAT1 suppresses the proliferation and migration of endothelial progenitor cells in deep vein thrombosis by regulating the Wnt\/\u03b2-catenin pathway","volume":"20","author":"Du","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1080\/21655979.2022.2080412","article-title":"Significant role of long non-coding RNA MALAT1 in deep vein thrombosis via the regulation of vascular endothelial cell physiology through the microRNA-383-5p\/BCL2L11 axis","volume":"13","author":"Wang","year":"2022","journal-title":"Bioengineered"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/svn-2022-001498","article-title":"MALAT1 promotes platelet activity and thrombus formation through PI3k\/Akt\/GSK-3\u03b2 signalling pathway","volume":"8","author":"Sun","year":"2022","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1515\/hsz-2019-0219","article-title":"Exosomal MALAT1 derived from ox-LDL-treated endothelial cells induce neutrophil extracellular traps to aggravate atherosclerosis","volume":"401","author":"Gao","year":"2020","journal-title":"Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"960317","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00280-010-1487-6","article-title":"Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy","volume":"68","author":"Shitara","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_48","first-page":"63","article-title":"Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer: A systematic review","volume":"2","author":"Eskander","year":"2012","journal-title":"J. Hematol. Malig."},{"key":"ref_49","unstructured":"Daniel, D., and Crawford, J. (2006). Seminars in Oncology, Elsevier."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6S8","DOI":"10.1016\/S2542-4513(20)30514-9","article-title":"Cancer and thrombosis: New insights to an old problem","volume":"45","author":"Leiva","year":"2020","journal-title":"JMV-J. M\u00e9decine Vasc."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Fantini, S., Rontauroli, S., Sartini, S., Mirabile, M., Bianchi, E., Badii, F., Maccaferri, M., Guglielmelli, P., Ottone, T., and Palmieri, R. (2021). Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 13.","DOI":"10.3390\/cancers13194744"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.biopha.2018.03.105","article-title":"Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma","volume":"102","author":"Toraih","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11906-023-01258-0","article-title":"Irregularities of Coagulation in Hypertension","volume":"25","author":"Rafaqat","year":"2023","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cll.2014.06.005","article-title":"Clinical use of the activated partial thromboplastin time and prothrombin time for screening: A review of the literature and current guidelines for testing","volume":"34","author":"Levy","year":"2014","journal-title":"Clin. Lab. Med."},{"key":"ref_55","first-page":"2644","article-title":"MALAT1 affects ovarian cancer cell behavior and patient survival","volume":"39","author":"Lin","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_56","first-page":"3703","article-title":"Long non-coding RNA MALAT1 regulates ovarian cancer cell proliferation, migration and apoptosis through Wnt\/\u03b2-catenin signaling pathway","volume":"22","author":"Guo","year":"2018","journal-title":"Eur. Rev Med. Pharmacol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Xu, X., Lv, H., Wen, Q., Li, J., Tan, L., Li, J., and Sheng, X. (2016). The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155250"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3892\/ol.2016.4800","article-title":"Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer","volume":"12","author":"Chen","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_59","first-page":"3176","article-title":"LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway","volume":"21","author":"Jin","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12959-022-00413-y","article-title":"Long noncoding RNA TUG1 induces angiogenesis of endothelial progenitor cells and dissolution of deep vein thrombosis","volume":"20","author":"Feng","year":"2022","journal-title":"Thromb. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/ijo.2020.5100","article-title":"Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics?","volume":"57","author":"Baliou","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Camilli, C., Hoeh, A.E., De Rossi, G., Moss, S.E., and Greenwood, J. (2022). LRG1: An emerging player in disease pathogenesis. J. Biomed. Sci., 29.","DOI":"10.1186\/s12929-022-00790-6"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.yexmp.2016.09.008","article-title":"Long non-coding RNA TUG1 regulates ovarian cancer proliferation and metastasis via affecting epithelial-mesenchymal transition","volume":"101","author":"Kuang","year":"2016","journal-title":"Exp. Mol. Pathol."},{"key":"ref_64","first-page":"5610","article-title":"AIB1 regulates the ovarian cancer cell cycle through TUG1","volume":"21","author":"Li","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e12131","DOI":"10.1097\/MD.0000000000012131","article-title":"LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1016\/j.ygeno.2020.08.005","article-title":"Tissue-based long non-coding RNAs \u201cPVT1, TUG1 and MEG3\u201d signature predicts Cisplatin resistance in ovarian Cancer","volume":"112","author":"Mohammed","year":"2020","journal-title":"Genomics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10760296231179447","DOI":"10.1177\/10760296231179447","article-title":"LncRNA NEAT1 Promotes Vascular Endothelial Cell Dysfunction via miR-218-5p\/GAB2 and Serves as a Diagnostic Biomarker for Deep Vein Thrombosis","volume":"29","author":"Wang","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_68","first-page":"3373","article-title":"Clinical significance of up-regulated lncRNA NEAT1 in prognosis of ovarian cancer","volume":"20","author":"Chen","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/cvr\/cvz085","article-title":"Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients","volume":"115","author":"Gast","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pro.3307","article-title":"The human protein atlas: A spatial map of the human proteome","volume":"27","author":"Thul","year":"2018","journal-title":"Protein Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jtha.2022.11.033","article-title":"Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease","volume":"21","author":"Girard","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2014.04.006","article-title":"Understanding the molecular pathogenesis of acute promyelocytic leukemia","volume":"27","author":"Hasan","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Zeng, C., Xu, Y., Xu, L., Yu, X., Cheng, J., Yang, L., Chen, S., and Li, Y. (2014). Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-693"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.2147\/OTT.S144438","article-title":"Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia","volume":"10","author":"Song","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00262-022-03305-2","article-title":"Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1\/miR-101-3p\/ZEB1\/PD-L1 axis","volume":"72","author":"Yin","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6256384","DOI":"10.1155\/2022\/6256384","article-title":"Knockdown of lncRNA XIST Ameliorates IL-1\u03b2-Induced Apoptosis of HUVECs and Change of Tissue Factor Level via miR-103a-3p\/HMGB1 Axis in Deep Venous Thrombosis by Regulating the ROS\/NF-\u03baB Signaling Pathway","volume":"2022","author":"Cao","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41598-018-20479-x","article-title":"Deep vein thrombosis in mice is regulated by platelet HMGB1 through release of neutrophil-extracellular traps and DNA","volume":"8","author":"Dyer","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Li, J., Wei, L., Han, Z., Chen, Z., and Zhang, Q. (2020). Long non-coding RNA X-inactive specific transcript silencing ameliorates primary graft dysfunction following lung transplantation through microRNA-21-dependent mechanism. EBioMedicine, 52.","DOI":"10.1016\/j.ebiom.2019.102600"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Chen, Z., Dai, Y., Lai, Y., Gao, F., and Wu, Y. (2023). Exploring the XIST axis as oxidative stress-related signatures in systemic lupus erythematosus. Clin. Exp. Rheumatol.","DOI":"10.55563\/clinexprheumatol\/e42fho"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41419-020-03358-0","article-title":"Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression","volume":"12","author":"Jiang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.2147\/OTT.S204369","article-title":"Long non-coding RNA XIST promotes malignant behavior of epithelial ovarian cancer","volume":"12","author":"Zuo","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3934\/mbe.2020110","article-title":"Long non-coding RNA XIST is down-regulated and correlated to better prognosis in ovarian cancer","volume":"17","author":"Yue","year":"2020","journal-title":"Math. Biosci. Eng."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bulut, N., and Kapagan, T. (2022). Do high pre-operative ca-125 levels predict early recurrence in patients with high-grade epithelial ovarian cancer?. Ponte Int. J. Sci. Res., 78.","DOI":"10.21506\/j.ponte.2022.8.8"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12935-022-02705-9","article-title":"A review on the role of MEG8 lncRNA in human disorders","volume":"22","author":"Khoshbakht","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-022-04812-z","article-title":"MEG8 regulates Tissue Factor Pathway Inhibitor 2 (TFPI2) expression in the endothelium","volume":"12","author":"Kremer","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/jog.15660","article-title":"The role of tissue factor pathway inhibitor 2 in the coagulation and fibrinolysis system","volume":"49","author":"Kobayashi","year":"2023","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_87","first-page":"199","article-title":"Does plasmin have anticoagulant activity?","volume":"6","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41416-022-01968-3","article-title":"Tissue factor in cancer-associated thromboembolism: Possible mechanisms and clinical applications","volume":"127","author":"Koizume","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13567-021-00908-y","article-title":"Expression analysis of tissue factor pathway inhibitors TFPI-1 and TFPI-2 in Paralichthys olivaceus and antibacterial and anticancer activity of derived peptides","volume":"52","author":"Wang","year":"2021","journal-title":"Vet. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/mco.2021.2479","article-title":"Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results","volume":"16","author":"Miyake","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000524804","article-title":"Tissue factor pathway inhibitor 2: A novel biomarker for predicting asymptomatic venous thromboembolism in patients with epithelial ovarian cancer","volume":"87","author":"Yamanaka","year":"2022","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/cam4.3854","article-title":"Identification of MEG8\/miR-378d\/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis","volume":"10","author":"Lei","year":"2021","journal-title":"Cancer Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10147-021-01914-y","article-title":"Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary","volume":"26","author":"Miyagi","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Arakawa, N., Kobayashi, H., Yonemoto, N., Masuishi, Y., Ino, Y., Shigetomi, H., Furukawa, N., Ohtake, N., Miyagi, Y., and Hirahara, F. (2016). Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165609"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1021\/pr400282j","article-title":"Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma","volume":"12","author":"Arakawa","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1111\/jog.14916","article-title":"Toward an understanding of tissue factor pathway inhibitor\u20142 as a novel serodiagnostic marker for clear cell carcinoma of the ovary","volume":"47","author":"Kobayashi","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0003319717732238","article-title":"Endothelial Dysfunction and Venous Thrombosis","volume":"69","author":"Poredos","year":"2018","journal-title":"Angiology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2174\/1381612827666210303143442","article-title":"Chronic inflammation and cancer: The role of endothelial dysfunction and vascular inflammation","volume":"27","author":"Malhab","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Bharadwaj, A.G., Holloway, R.W., Miller, V.A., and Waisman, D.M. (2021). Plasmin and plasminogen system in the tumor microenvironment: Implications for cancer diagnosis, prognosis, and therapy. Cancers, 13.","DOI":"10.3390\/cancers13081838"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3324\/haematol.2016.147405","article-title":"Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism","volume":"101","author":"Gran","year":"2016","journal-title":"Haematologica"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(15)50432-5","article-title":"The mechanisms of cancer-associated thrombosis","volume":"135","author":"Falanga","year":"2015","journal-title":"Thromb. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:37Z","timestamp":1760132377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010140"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010140","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}